サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1750862

予測バイオマーカーの市場規模、シェア、動向分析レポート：適応症別、技術別、地域別、セグメント予測、2025年～2030年

Predictive Biomarkers Market Size, Share & Trends Analysis Report By Indication, By Technology (Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
予測バイオマーカーの市場規模、シェア、動向分析レポート：適応症別、技術別、地域別、セグメント予測、2025年～2030年
出版日: 2025年05月30日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

予測バイオマーカー市場サマリー

予測バイオマーカーの世界市場規模は、2024年に243億米ドルと推計され、2025年から2030年にかけて18.02%のCAGRで成長し、2030年には635億4,000万米ドルに達すると予測されます。同市場は、ゲノミクスや精密医療の進歩、研究開発投資の増加、早期発見や個別化治療に対する需要の高まりなど、いくつかの要因によって大きな成長を遂げています。

研究開発（R&D）は予測バイオマーカー市場の成長の主要な促進要因であり、技術革新と新たなバイオマーカー候補の発見に拍車をかけています。ゲノミクスと精密医療は医療技術の最前線にあり、より的を絞った効果的な治療の可能性を提供しています。介入効果の予測バイオマーカーは、個人の生物学的構成要素（「宿主特性」）、または疾患プロセスや他の病状に関連する特性を反映することができます。NHSと政府は、NHSゲノム医療サービス（NHS Genomic Medicine Service）の開始を含め、これらの技術に多大な投資を行っています。このサービスは、ゲノム配列決定の実施、がん患者への分子診断と遺伝子検査の提供、より効果的な治療を促進するためのデータ統合の強化など、患者のためになるゲノミクスの進歩に特化しています。さらに、新しいシーケンシング技術の開発に精通した技術およびデータ解析の専門知識は、イノベーションと効果的な治療を促進するコラボレーションを通じて達成されます。

例えば、2025年4月、イルムニアはTempus AIと提携し、患者への次世代シーケンシング検査の導入を加速させました。

研究開発（R&D）への投資の拡大は、予測バイオマーカー市場の主要な促進要因です。製薬会社、バイオテクノロジー企業、学術機関は、新しいバイオマーカーの発見と診断技術の進歩に多大なリソースを投入しています。バイオマーカー同定の有力なアプリケーションの1つが次世代シーケンサー（NGS）であり、遺伝子内の数百万コピーのDNAを迅速に検出することができます。この技術により、短時間で複数の遺伝子や変異の包括的なプロファイリングが可能になります。例えば、イルミナのNovaSeq Xプラットフォームは、大量シーケンスのデータ解析や病態診断のためのハイスループットシーケンスを提供しています。バイオマーカー探索における資金提供や共同作業の増加は、より効果的で正確な予測検査の開発につながります。その結果、予測バイオマーカー市場の成長が加速し、次世代のヘルスケアイノベーションを支えています。

疾病の早期発見と個別化治療に対する需要の高まりは、予測バイオマーカー市場の主要な促進要因の一つです。バイオマーカーは個人の健康状態に関する貴重な洞察を提供し、症状が現れる前の初期段階で病気を特定するのに役立ちます。早期発見はより効果的な介入を可能にし、患者の転帰を改善し、治療費を削減します。予測バイオマーカーの重要な応用分野は腫瘍学であり、乳がん患者の死亡率の主要因であり続ける治療抵抗性を示すことから、予測バイオマーカー開発の必要性が高まっています。

オミックス技術や人工知能のような革新的なアプローチは、高精度の分子バイオマーカーや画像バイオマーカーを同定するために研究されており、治療成績を向上させる可能性を秘めています。バイオマーカーは、安全性試験や有効性試験のために臨床試験に組み入れられることが一般的になりつつあります。予測バイオマーカーは、患者のニーズに応じて医薬品を調整する臨床試験の一部となる可能性もあります。ヘルスケアシステムが個別化医療へとシフトする中、予測バイオマーカーは、治療レジメンを最適化し、各患者に適した治療を確実に行う上で重要な役割を果たします。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 予測バイオマーカー市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 予測バイオマーカー市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 予測バイオマーカー市場：適応症の推定・動向分析

  • セグメントダッシュボード
  • 予測バイオマーカー市場：変動分析
  • 予測バイオマーカー市場規模と動向分析（2018年～2030年）
  • 予測バイオマーカー市場収益推計と予測（2018年～2030年）
  • がん
  • 心血管疾患
  • 神経疾患
  • 免疫疾患
  • その他

第5章 予測バイオマーカー市場：技術推定・動向分析

  • 市場シェア、2024年と2030年
  • セグメントダッシュボード
  • 世界の予測バイオマーカー市場展望
  • 市場規模と予測および動向分析（2018年～2030年）
  • 診断
  • 医薬品の発見と開発
  • パーソナライズ医療
  • 疾病リスク評価
  • その他

第6章 予測バイオマーカー市場：地域推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 世界地域市場のスナップショット
  • 市場規模、予測動向分析、2018年から2030年まで：
  • 北米
    • 北米： SWOT分析
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州： SWOT分析
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • アジア太平洋地域： SWOT分析
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ラテンアメリカ： SWOT分析
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • MEA：SWOT分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店およびチャネルパートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析（2024年）
    • Thermo Fisher Scientific Inc.
    • Qiagen
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories, Inc
    • Agilent Technologies, Inc.
    • Illumina Inc.
    • Merck KGaA
    • Bio-Techne
    • Siemens Healthineers AG
    • PerkinElmer
    • Myriad Genetics, Inc.
    • Becton Dickinson
    • Danaher Corporation
    • Genomic Health, Inc.
    • PacBio
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Predictive biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 4 North America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 7 Canada Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 8 Canada Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 9 Mexico Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 10 Mexico Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 11 Europe Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Europe Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 13 UK Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 14 UK Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 15 Germany Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 16 Germany Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 17 France Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 18 France Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 19 Italy Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Italy Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Spain Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 22 Spain Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 23 Denmark Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Denmark Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Sweden Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Sweden Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Norway Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Norway Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 31 Japan Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 32 Japan Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 33 China Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 34 China Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 35 India Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 36 India Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 37 Australia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Australia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 39 South Korea Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 40 South Korea Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 41 Thailand Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 42 Thailand Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 43 Latin America Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Latin America Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Brazil Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 46 Brazil Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 47 Argentina Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Argentina Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 49 MEA Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 50 MEA Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 51 South Africa Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 52 South Africa Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 55 UAE Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 56 UAE Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Predictive biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Predictive biomarkers market, by technology, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Predictive biomarkers market: market outlook
  • Fig. 14 Predictive biomarkers competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Predictive biomarkers market driver impact
  • Fig. 20 Predictive biomarkers market restraint impact
  • Fig. 21 Predictive biomarkers market strategic initiatives analysis
  • Fig. 22 Predictive biomarkers market: Indication movement analysis
  • Fig. 23 Predictive biomarkers market: Indication outlook and key takeaways
  • Fig. 24 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 25 Cardiovascular Diseases market estimates and forecasts,2018 - 2030
  • Fig. 26 Neurological Diseases market estimates and forecasts,2018 - 2030
  • Fig. 27 Immunological Diseases market estimates and forecasts,2018 - 2030
  • Fig. 28 Others market estimates and forecasts,2018 - 2030
  • Fig. 29 Predictive biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 30 Predictive biomarkers Market: Technology movement analysis
  • Fig. 31 Predictive biomarkers market: Technology outlook and key takeaways
  • Fig. 32 Diagnostics market estimates and forecasts, 2018 - 2030
  • Fig. 33 Drug Discovery & Development market estimates and forecasts, 2018 - 2030
  • Fig. 34 Personalized Medicine market estimates and forecasts, 2018 - 2030
  • Fig. 35 Disease Risk Assessment market estimates and forecasts, 2018 - 2030
  • Fig. 36 Others market estimates and forecasts,2018 - 2030
  • Fig. 37 Global Predictive biomarkers market: Regional movement analysis
  • Fig. 38 Global Predictive biomarkers market: Regional outlook and key takeaways
  • Fig. 39 Global Predictive biomarkers market share and leading players
  • Fig. 40 North America market share and leading players
  • Fig. 41 Europe market share and leading players
  • Fig. 42 Asia Pacific market share and leading players
  • Fig. 43 Latin America market share and leading players
  • Fig. 44 Middle East & Africa market share and leading players
  • Fig. 45 North America, by country
  • Fig. 46 North America
  • Fig. 47 North America market estimates and forecasts, 2018 - 2030
  • Fig. 48 U.S.
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada
  • Fig. 51 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 52 Mexico
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 54 Europe
  • Fig. 55 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 56 UK
  • Fig. 57 UK market estimates and forecasts, 2018 - 2030
  • Fig. 58 Germany
  • Fig. 59 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 60 France
  • Fig. 61 France market estimates and forecasts, 2018 - 2030
  • Fig. 62 Italy
  • Fig. 63 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 64 Spain
  • Fig. 65 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 66 Denmark
  • Fig. 67 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 68 Sweden
  • Fig. 69 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 70 Norway
  • Fig. 71 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 72 Asia Pacific
  • Fig. 73 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 74 China
  • Fig. 75 China market estimates and forecasts, 2018 - 2030
  • Fig. 76 Japan
  • Fig. 77 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 78 India
  • Fig. 79 India market estimates and forecasts, 2018 - 2030
  • Fig. 80 Thailand
  • Fig. 81 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 82 South Korea
  • Fig. 83 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 84 Australia
  • Fig. 85 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 86 Latin America
  • Fig. 87 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 88 Brazil
  • Fig. 89 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 90 Argentina
  • Fig. 91 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 92 Middle East and Africa
  • Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 South Africa
  • Fig. 95 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 96 Saudi Arabia
  • Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 98 UAE
  • Fig. 99 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 100 Kuwait
  • Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 102 Market share of key market players - Predictive biomarkers market
目次
Product Code: GVR-4-68040-593-9

Predictive Biomarkers Market Summary

The global predictive biomarkers market size was estimated at USD 24.30 billion in 2024 and is projected to reach USD 63.54 billion by 2030, growing at a CAGR of 18.02% from 2025 to 2030. The market is experiencing significant growth driven by several factors such as advancements in genomics and precision medicines, increased investment in research and development and rising demand for early detection and personalized treatments.

Research and development (R&D) is a major driver of growth in the predictive biomarkers market, fueling innovation and the discovery of new biomarker candidates. Genomics and precision medicine are at the forefront of medical technology, offering the potential for more targeted and effective treatments. Predictive biomarkers for the effects of interventions can reflect an individual's biological constituents ("host characteristics") or traits associated with the disease process or other medical conditions. The NHS and the government are making significant investments in these technologies, including the launch of the NHS Genomic Medicine Service. This service is dedicated to advancements in genomics to benefit patients by implementing genome sequencing, providing molecular diagnostics and genetic testing for cancer patients, and enhancing data integration to facilitate more effective treatments. Moreover, expertise in technology and data analytics with proficiency in developing new sequencing technologies, is

achieved through collaborations that drive innovation and advance precision medicine for instance, in April 2025, Illumnia collaborated with Tempus AI to accelerate adoption of next generation sequencing tests for patients.

The growing investment in research and development (R&D) is a key driver of the predictive biomarkers market. Pharmaceutical companies, biotech firms, and academic institutions are dedicating significant resources to discovering new biomarkers and advancing diagnostic technologies. One prominent application for biomarker identification is next-generation sequencing (NGS), which can rapidly detect millions of DNA copies within a gene. This technology enables comprehensive profiling of multiple genes and mutations in a short amount of time. For example, Illumina's NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of disease. The increasing funding and collaborative efforts in biomarker discovery lead to the development of more effective and accurate predictive tests. This, in turn, is accelerating the growth of the predictive biomarkers market, supporting the next generation of healthcare innovations.

There is an increasing demand for early disease detection and personalized treatments, which is one of the key driver in predictive biomarkers market. Biomarkers provide valuable insights into an individual's health, helping identify diseases in their early stages before symptoms appear. Early detection enables more effective interventions, improving patient outcomes and reducing treatment costs. An important application of predictive biomarkers is in oncology, which demonstrates resistance to treatment that continues to be a leading cause of mortality in breast cancer patients, driving the need for the development of predictive biomarkers.

Innovative approaches, such as omics technologies and artificial intelligence, are being explored to identify highly accurate molecular or imaging biomarkers, with the potential to enhance treatment outcomes. Biomarkers are even gaining popularity incorporation into clinical trials for safety and efficacy tests. Predictive biomarkers may also become a part of these trials tailoring of medicines according to patient needs. As healthcare systems shift toward individualized medicine, predictive biomarkers play a crucial role in optimizing treatment regimens and ensuring the right therapy for each patient.

Global Predictive Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global predictive biomarkers market report on the basis of indication, technology and region.

  • Indication Outlook (Revenue, USD Million, 2018 - 2030)
  • Cancer
  • Cardiovascular Diseases
  • Neurological Diseases
  • Immunological Diseases
  • Others
  • Technology Outlook (Revenue, USD Million, 2018 - 2030)
  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Others
  • Regional Outlook (Revenue in USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Technology
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication outlook
    • 2.2.2. Technology outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Predictive Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Predictive Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Predictive Biomarkers Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Predictive Biomarkers Market: Indication Movement Analysis
  • 4.3. Predictive Biomarkers Market Size & Trend Analysis, by indication, 2018 to 2030 (USD Million)
  • 4.4. Predictive Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Cancer
    • 4.5.1. Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Cardiovascular Diseases
    • 4.6.1. Cardiovascular Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Neurological Diseases
    • 4.7.1. Neurological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Immunological Diseases
    • 4.8.1. Immunological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Predictive Biomarkers Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Predictive Biomarkers Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Diagnostics
    • 5.5.1. Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Drug Discovery & Development
    • 5.6.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Personalized Medicine
    • 5.7.1. Personalized Medicine Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Disease Risk Assessment
    • 5.8.1. Disease Risk Assessment Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Predictive Biomarkers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. North America: SWOT Analysis
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/Reimbursement
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/Reimbursement
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/Reimbursement
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe: SWOT Analysis
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/Reimbursement
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/Reimbursement
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/Reimbursement
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/Reimbursement
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/Reimbursement
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/Reimbursement
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/Reimbursement
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/Reimbursement
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific: SWOT Analysis
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/Reimbursement
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/Reimbursement
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/Reimbursement
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/Reimbursement
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/Reimbursement
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework/Reimbursement
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America: SWOT Analysis
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/Reimbursement
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/Reimbursement
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA: SWOT Analysis
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/Reimbursement
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/Reimbursement
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/Reimbursement
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. Thermo Fisher Scientific Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Services benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Qiagen
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Services benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. F. Hoffmann-La Roche Ltd
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Services benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Bio-Rad Laboratories, Inc
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Services benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Agilent Technologies, Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Services benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Illumina Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Services benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Merck KGaA
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Services benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Bio-Techne
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Services benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Siemens Healthineers AG
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Services benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. PerkinElmer
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Services benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Myriad Genetics, Inc.
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Services benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. Becton Dickinson
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Services benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. Danaher Corporation
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Services benchmarking
      • 7.3.16.4. Strategic initiatives
    • 7.3.17. Genomic Health, Inc.
      • 7.3.17.1. Company overview
      • 7.3.17.2. Financial performance
      • 7.3.17.3. Services benchmarking
      • 7.3.17.4. Strategic initiatives
    • 7.3.18. PacBio
      • 7.3.18.1. Company overview
      • 7.3.18.2. Financial performance
      • 7.3.18.3. Services benchmarking
      • 7.3.18.4. Strategic initiatives